CA2298107A1 - Utilisation du facteur de transcription brn-3a - Google Patents

Utilisation du facteur de transcription brn-3a Download PDF

Info

Publication number
CA2298107A1
CA2298107A1 CA002298107A CA2298107A CA2298107A1 CA 2298107 A1 CA2298107 A1 CA 2298107A1 CA 002298107 A CA002298107 A CA 002298107A CA 2298107 A CA2298107 A CA 2298107A CA 2298107 A1 CA2298107 A1 CA 2298107A1
Authority
CA
Canada
Prior art keywords
brn
vector
polynucleotide
polypeptide
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002298107A
Other languages
English (en)
Inventor
Martin Damian Smith
David Seymour Latchman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovex Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9715823.2A external-priority patent/GB9715823D0/en
Application filed by Individual filed Critical Individual
Publication of CA2298107A1 publication Critical patent/CA2298107A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002298107A 1997-07-25 1998-07-27 Utilisation du facteur de transcription brn-3a Abandoned CA2298107A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9715823.2A GB9715823D0 (en) 1997-07-25 1997-07-25 Use of transcription factor BRN-3A
GB9715823.2 1997-07-25
US98847697A 1997-12-10 1997-12-10
US988,476 1997-12-10
PCT/GB1998/002228 WO1999005272A1 (fr) 1997-07-25 1998-07-27 Utilisation du facteur de transcription brn-3a

Publications (1)

Publication Number Publication Date
CA2298107A1 true CA2298107A1 (fr) 1999-02-04

Family

ID=26311947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002298107A Abandoned CA2298107A1 (fr) 1997-07-25 1998-07-27 Utilisation du facteur de transcription brn-3a

Country Status (6)

Country Link
EP (1) EP1003859A1 (fr)
JP (1) JP2001511344A (fr)
AU (1) AU8548198A (fr)
CA (1) CA2298107A1 (fr)
IL (1) IL134210A0 (fr)
WO (1) WO1999005272A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9819999D0 (en) * 1998-09-14 1998-11-04 Univ London Treatment of cancer
WO2000034466A1 (fr) * 1998-12-07 2000-06-15 University College London Traitement du cancer du col de l'uterus
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
KR100820072B1 (ko) * 2002-12-28 2008-04-10 (주)아모레퍼시픽 진세노사이드 F1을 유효성분으로 하는 Bcl-2 발현조절제
JP3870921B2 (ja) 2003-04-01 2007-01-24 セイコーエプソン株式会社 非接触識別タグ
KR100868905B1 (ko) * 2004-03-26 2008-11-14 (주)아모레퍼시픽 진세노사이드 f1과 egcg을 함유한 자외선 조사로유도되는 피부손상 방지용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof

Also Published As

Publication number Publication date
IL134210A0 (en) 2001-04-30
WO1999005272A9 (fr) 1999-10-28
EP1003859A1 (fr) 2000-05-31
JP2001511344A (ja) 2001-08-14
WO1999005272A1 (fr) 1999-02-04
AU8548198A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
Azmitia et al. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor
Lamballe et al. trkC encodes multiple neurotrophin‐3 receptors with distinct biological properties and substrate specificities.
AU749017B2 (en) Mutant herpes simplex viruses and uses thereof
Attree et al. The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase
JP5108797B2 (ja) 色素上皮誘導因子:pedf遺伝子の特性評価、ゲノム構成および配列
US6106826A (en) Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
EP0938553B1 (fr) Adn codant dp-75 et procede d'utilisation
JP2001508294A (ja) 真核細胞遺伝子発現カセットおよびその使用
CA2298107A1 (fr) Utilisation du facteur de transcription brn-3a
US7329741B2 (en) Polynucleotides that hybridize to DP-75 and their use
CZ288882B6 (cs) Polynukleotid, antimediátorový polynukleotid, polypeptid kódovaný uvedeným polynukleotidem, vektor obsahující uvedený polynukleotid, farmaceutická kompozice obsahující uvedený polynukleotid nebo antimediátorový polynukleotid nebo polypeptid nebo vektor a jejich použití pro přípravu farmaceutické kompozice
US7060429B2 (en) Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
US6194175B1 (en) Nucleic acids encoding truncated forms of inhibitory kappa B protein
EP1572887A2 (fr) Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales
WO1997010349A1 (fr) Matieres et procedes de traitement de maladies neurodegeneratives et de recherche systematique d'inhibiteurs et d'inducteurs potentiels de l'apoptose
EP1685151A2 (fr) Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux
WO2003071872A1 (fr) Nouveau traitement de maladies neurodegeneratives par modification de niveaux d'isoformes trkb et/ou trkc
Yang et al. Sustained expression of functional nerve growth factor in primary septo-hippocampal cell cultures by liposome-mediated gene transfer
WO1998019686A9 (fr) Methodes therapeutiques pour lesion vasculaire
US20060148749A1 (en) Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms
EP0535337A2 (fr) Activités inhibitrices de la croissance des cellules du facteur promoteur de la croissance des neurites et se liant à l'héparine
EP0535336A2 (fr) Protéine MK comme inhibiteur de la croissance des cellules
WO2002067858A2 (fr) Nouveau traitement de maladies neuro-degeneratives par modification des proportions d'isoformes trkb et/ou trkc
US5952213A (en) Src-family kinase and methods of use thereof
US6998475B1 (en) Variants of traf2 which act as an inhibitor of tnf-alpha (tnfα) signaling pathway

Legal Events

Date Code Title Description
FZDE Discontinued